findmyKOL

Michael Augenbraun, MD

Basic profile

SUNY Downstate Health Sciences University

ORCIDNPI
RegionBrooklyn, NY · NortheastSpecialtyInfectious DiseaseFocusInfectious Disease
Last active 2022findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPaymentsNone reportedNIH funding1999–2000Why? →

Michael Augenbraun is an Infectious Disease physician affiliated with SUNY Downstate Health Sciences University. OpenAlex indexes 148 publications with 5,014 citations (h-index 34).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
148publications

Distinct works indexed by OpenAlex, matched via ORCID.

5,014citations

Total citations across indexed works.

34h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1NIH grants · 1999–2000

Federally funded research awards.

View funding

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    41.6%
    Statin11.1%
    Atorvastatin Calcium57%Rosuvastatin Calcium43%
    Part D<11 patients
    Calcium channel blocker8.3%
    Amlodipine Besylate100%
    Part D13 patients

    + 5 more classes in this area

  • Anti-infectives

    23%
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor10.4%
    Triumeq38%Emtricitabine-Tenofovir Disop32%Descovy30%
    Part D<11 patients
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor5.4%
    Tivicay59%Cabenuva41%
    Part D<11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    22.1%
    Biguanide (metformin)9.5%
    Metformin Hcl100%
    Part D<11 patients
    DPP-4 inhibitor4.3%
    Januvia100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B), 2022100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 19992000 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”